CA-INGRAM-MICRO
4.5.2021 14:05:12 CEST | Business Wire | Press release
Growing its Artificial Intelligence (AI) portfolio, Ingram Micro Inc. today announced an expanded, and now global, business relationship with UiPath , a leading enterprise automation software company and Robotic Process Automation (RPA) tech innovator.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005476/en/
RPA enables organizations in the digital transformation (DX) era to increase efficiency, workflow determinism, operation accuracy and compliance with regulations by automating repetitive and time-consuming mundane tasks. Additionally, software robots work to establish end-to-end automation across the organization while driving costs down. Ingram Micro’s broad and specialized Advanced Solutions portfolio began offering AI and RPA solutions a few years ago and has become one of the organization’s fastest-growing global practices.
“Robotic process automation is an important component within a company’s digital transformation game plan, and a great sales wedge for channel partners to introduce DX solutions and services into their existing end user customer base,” said Sabine Howest, vice president, global partner engagement and IoT, Ingram Micro Inc. “Using AI to automate repeatable, rules-driven processes is a practice companies of all sizes can benefit from and a growth opportunity we’re ready to drive with UiPath through our growing and global Advanced Solutions organization.”
“We’re thrilled that UiPath is offering additional support to high-value service providers like us through its new Ingram Micro program,” said Bhavyesh Virani, co-CEO of WonderBotz, a UiPath partner. “Ingram Micro’s global reach will help WonderBotz capture the rising demand for our custom services as well as for our prebuilt turnkey solutions for F&A professionals and healthcare, finance, banking, and hospitality leaders. The new UiPath/Ingram Micro program is an all-around win, enabling us to spend more time on delivering industry-leading client services.”
Ingram Micro’s relationship with UiPath started in India in 2018 and was quickly followed by China. Currently, the relationship is now expanded to North America and Latin America as well as Europe, Middle East, Africa, and the remainder of Asia Pacific. The team at Ingram Micro maintains a mature and dedicated UiPath team of experts who are here to help channel partners throughout the sales cycle including opportunity identification, design thinking, advisory services, licensing and training. With the support of Ingram Micro’s Centers of Excellence, channel partners selling UiPath benefit from shared best practices, “follow the sun” support services and global resources designed to meet the varied demands of the market locally, regionally, and globally.
“Ingram Micro and UiPath are partner-first organizations equally committed to continually investing in our partners to drive greater service differentiation, exceptional growth, and improved profitability,” says Thomas Hansen, Chief Revenue Officer, UiPath. “Enterprise automation is a category channel partners cannot ignore, and an investment enterprise organizations are making because of the immediate and measurable return on investment and improvement to the associate experience and the customer experience. We are thrilled to expand our successful relationship with Ingram Micro worldwide and look forward to helping channel partners capitalize on the market potential for RPA.”
In Q1 2021, the Forrester Wave™*: Robotic Process Automation named UiPath “a Leader” with the highest ranking in each of three categories: Current Offering, Strategy, and Market Presence. Additionally, UiPath Vice President of Global Alliances and Partners, Cheryln Chin, and Senior Vice President of Operations and Partners, Eddie O’Brien were recently named to the 2021 CRN Channel Chiefs list, along with eight Ingram Micro channel executives.
The entire UiPath portfolio is now available to Ingram Micro channel partners worldwide. To learn more about UiPath, contact your Ingram Micro partner manager. For Quote to order support, please email: UiPath-licensing@ingrammicro.com and for sales and pre-sales support, please email: UiPath-sd@ingrammicro.com .
*The Forrester Wave™: Robotic Process Automation, Q1 2021, March 15, 2021
About UiPath
UiPath has a vision to deliver the Fully Automated Enterprise™, one where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005476/en/
Link:
Social Media:
https://www.facebook.com/IngramMicroLatinAmericaDivision
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom